ENTITY
Lupin

Lupin (LPC IN)

279
Analysis
Health Care • India
Lupin is an Indian multinational pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company specializes in therapeutic areas such as cardiovascular, anti-diabetic, respiratory, anti-infective, and women's health. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
more
•12 Oct 2022 00:16•Broker

Pharma Q2fy23 Preview

The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY. Currency (Rs) has depreciated by 5.0%

Logo
263 Views
Share
•31 Dec 2016 20:34•Syndicated

Pakistan Market Outlook 2017

Pakistan market is expected to continue its uptrend in 2017 given tangible gains from China Pakistan Economic Corridor (CPEC) projects and rising...

Logo
572 Views
Share
bullish•Lupin
•07 Aug 2023 21:27•Broker

LUPIN Ltd - Positive Outlook Backed by the Launch of Niche Products

The company’s sales were up 28.6% YoY at Rs 4,330 Cr, and the growth was majorily led by its India business (+9.8% YoY), EMEA (+19.6% YoY)

Logo
391 Views
Share
bullish•Lupin
•11 Jul 2023 09:19•Broker

Pick of the Week: Lupin Ltd - 10 JULY 2023

Lupin is an innovation-led transnational pharmaceutical company. It, develops and commercializes a wide range of branded and generic formulations,...

Logo
361 Views
Share
bullish•Lupin
•22 Jun 2023 08:18•Broker

Lupin - GSpiriva Approval a Overall Turnaround in The Business

Lupin has received approval from generic version of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) from USFDA in the US Market.

Logo
395 Views
Share
x